Search results
-
Triple meeting 2025 – Astellas touts a degrader turnaround
… At ESMO 2024, Astellas’s KRAS G12D degrader ASP3082 looked …
- 10/30/2025 - 13:41 -
ESMO 2025 – J&J brings a new Rybrevant use into the fold
… After Johnson & Johnson’s Rybrevant intrigued at ESMO 2024 in colorectal cancer the company now has its eye …
- 10/20/2025 - 12:52 -
Incyte goes pivotal in CDK2
… & ovarian cancers +/- Ibrance, +/- Faslodex; data at ESMO 2024 + atirmociclib (CDK4i) in breast cancer: 28% ORR …
- 10/16/2025 - 12:33 -
J&J goes straight into phase 3 in prostate
… an anti-Steap1 T-cell engager. Still, data presented at ESMO 2024 showed efficacy broadly in line with ARX517 and …
- 09/16/2025 - 14:56 -
J&J’s bladder hope gets its first approval
… cystectomy + cetrelimab, vs cetrelimab Data at ESMO 2024: pCR 42% with TAR-200 + cetrelimab, vs 23% with …
- 09/12/2025 - 10:17 -
Nuvation gets in before Nuvalent
… has 11 to 20-fold selectivity for ROS1 over TRK. In an ESMO 2024 poster Nuvalent put this at a more conservative …
- 06/16/2025 - 13:48 -
ASCO 2025 – BioNTech’s latest Claudin6 effort falls short
… *another 4 responses were unconfirmed. Source: ASCO 2025 & ESMO 2024. Complicating the cross-trial comparison …
- 06/01/2025 - 21:08 -
Another TIGIT bites the dust
… + Jemperli, vs Jemperli ORR ORR improvement at ESMO 2024; no meaningful improvement in PFS, as per May 2025 …
- 05/14/2025 - 15:34 -
Qilu nabs a new B7-H3 contender
… China ph3s in SCLC & head & neck Looked competitive at ESMO 2024 in SCLC MHB088C Minghui/ Qilu Topo1 …
- 05/13/2025 - 16:22 -
AACR 2025 preview – distressed biotechs seek redemption
… Ph1 in KRAS G12D-resistant NSCLC Had data at ESMO 2024 IK-595 MEK-RAF molecular glue Ikena …
- 03/28/2025 - 08:55
